Attorney Jessie Paluch, founder of TruLaw, has over 25 years of experience as a personal injury and mass tort attorney, and previously worked as an international tax attorney at Deloitte. Jessie collaborates with attorneys nationwide — enabling her to share reliable, up-to-date legal information with our readers.
This article has been written and reviewed for legal accuracy and clarity by the team of writers and legal experts at TruLaw and is as accurate as possible. This content should not be taken as legal advice from an attorney. If you would like to learn more about our owner and experienced injury lawyer, Jessie Paluch, you can do so here.
TruLaw does everything possible to make sure the information in this article is up to date and accurate. If you need specific legal advice about your case, contact us by using the chat on the bottom of this page. This article should not be taken as advice from an attorney.
On this page, we’ll provide an overview of the Taxotere lawsuit for vision damage, research linking Taxotere to vision damage, long term health risks of Taxotere treatments, and much more.
Taxotere may secrete into the tear ducts and cause severe damage.
Plaintiffs in the Taxotere MDL 3023 claim Sanofi-Aventis, (the manufacturer of Taxotere), did not adequately warn doctors about the risks of eye injuries potentially resulting in permanent vision loss.
The potential side effects of this chemotherapy drug can cause substantial discomfort, hinder everyday activities, and reduce your overall quality of life.
Reported injuries include a range of vision-related side effects, such as:
These conditions may lead to permanent vision damage.
If you or a loved one has developed vision damage or other vision problems after the using Taxotere, you may be eligible to seek financial compensation.
Contact TruLaw using the chat on this page to receive an instant case evaluation and determine you eligibility to join others in filing Taxotere vision damage lawsuits today.
The Taxotere Eye Injury Lawsuit involves claims against Sanofi, with plaintiffs alleging that the chemotherapy drug Taxotere causes severe eye injuries, such as excessive tearing and vision issues.
In September, the Judicial Panel on Multidistrict Litigation (JPML) reported 320 active lawsuits related to Taxotere.
By October, the number of cases slightly decreased to 312, reflecting a drop of 8 cases.
Despite this decline, the ongoing volume of lawsuits indicates persistent concerns about the drug’s side effects and insufficient warnings.
If you or a loved one experienced eye injuries or suffered vision loss after Taxotere use, you may be eligible to file a Taxotere Eye Injury Lawsuit and pursue financial compensation.
Contact TruLaw for a free consultation.
You can also use the chatbot on this page to find out if you qualify for the Taxotere Eye Injury Lawsuit instantly.
September 20, 2024
The Taxotere litigation experienced a quiet week, but this lull doesn’t signify any meaningful developments for current or potential plaintiffs. Mass tort litigation often involves behind-the-scenes work during seemingly inactive periods. Our lawyers remain available to discuss potential Taxotere lawsuits and offer free consultations to interested parties.
September 13, 2024
Taxotere lawsuits total over 9,000, with hair loss claims dominating the docket. Vision loss claims account for 320 pending lawsuits, a significant increase from August. Experts anticipate a continued rise in these cases as public awareness grows about Taxotere’s potential vision-related risks. The expanding number of vision loss claims highlights the evolving nature of the litigation.
September 6, 2024
The Taxotere litigation continues actively despite the absence of new updates this week. We encourage individuals who believe they suffered hair loss or vision damage from Taxotere to seek legal counsel. Our team offers free consultations to discuss potential claims and legal rights related to Taxotere usage.
The Taxotere Eye Injury Lawsuit is ongoing.
The lawsuit involves claims against Sanofi regarding the chemotherapy drug Taxotere.
Plaintiffs allege that Taxotere causes severe eye injuries, including excessive tearing and vision problems.
In July, there were 301 filings in the Taxotere Eye Injury lawsuit.
By August, this number increased to 308 filings.
The rise in filings indicates growing awareness and concern about the potential eye-related side effects of Taxotere, leading more individuals to seek legal action.
Taxotere, used in chemotherapy treatment, has been reported to cause eye injuries such as excessive tearing and vision impairment.
These side effects can significantly impact patients’ quality of life, prompting many affected individuals to file lawsuits against Sanofi for failing to provide adequate warnings about these risks.
If you or a loved one experienced eye injuries or suffered vision loss after Taxotere use, you may be eligible to file a Taxotere Eye Injury Lawsuit and pursue financial compensation.
Contact TruLaw for a free consultation.
You can also use the chatbot on this page to find out if you qualify for the Taxotere Eye Injury Lawsuit instantly.
July 17, 2024
The Taxotere Eye Injury Lawsuit is ongoing, and our lawyers are still accepting cases from those affected by eye injuries linked to the chemotherapy drug Taxotere.
Taxotere lawsuits primarily involve claims of excessive tearing, canalicular stenosis, tear duct damage, and other severe eye conditions resulting from the use of the drug.
The core arguments in the Taxotere Eye Injury lawsuits revolve around:
Healthcare professionals recommend the following precautions for those using Taxotere:
If you or a loved one experienced eye injuries or suffered vision loss after Taxotere use, you may be eligible to file a Taxotere Eye Injury Lawsuit and pursue financial compensation.
Contact TruLaw for a free consultation.
You can also use the chatbot on this page to find out if you qualify for the Taxotere Eye Injury Lawsuit instantly.
July 1, 2024
The Taxotere eye injury lawsuit is ongoing.
The Taxotere Eye Injury lawsuit involves claims that the chemotherapy drug Taxotere causes significant eye injuries, including excessive tearing and permanent damage.
In June, there were 273 Taxotere Eye Injury lawsuit filings.
By July, this number increased to 301, reflecting growing awareness of the risks associated with Taxotere.
Taxotere causes eye injuries by damaging the tear ducts, leading to chronic tearing, infections, and potential vision loss.
These severe impacts have prompted more individuals to join the Taxotere Eye Injury lawsuit.
The Taxotere Eye Injury lawsuit aims to hold the manufacturer responsible for the harm caused by the drug.
Affected individuals should consult a Taxotere Eye Injury lawyer to explore their legal options.
If you or a loved one has been negatively affected by Taxotere, call TruLaw today and receive a free consultation.
You can also use the chatbot on this page for an instant Taxotere Eye Injury case evaluation.
The Taxotere Eye Injury Lawsuit is currently active, and our attorneys are open to taking on new cases.
Recent updates from the Judicial Panel on Multidistrict Litigation (JPML) indicate that there are now 276 pending lawsuits concerning Taxotere Eye Injuries awaiting consolidation.
These legal actions are linked to eye injuries purportedly caused by the chemotherapy drug Taxotere.
Plaintiffs claim that Sanofi-Aventis, the drug’s manufacturer, failed to provide sufficient warnings to patients and healthcare providers about the risk of severe and potentially permanent eye complications, such as canal stenosis, associated with the drug.
If you or someone close to you has experienced eye injuries or vision loss following the use of Taxotere, you might be eligible to participate in the Taxotere Eye Damage Lawsuits.
Additionally, you can use the chatbot on this page to instantly check if you qualify for the Taxotere Vision Damage Lawsuit.
May 24, 2024
The Taxotere Eye Injury Lawsuit continues, and our attorneys are currently accepting new claims.
Taxotere has been linked to canalicular stenosis, a serious condition characterized by excessive eye watering that can lead to further vision complications.
This issue arises when the tear ducts become inflamed and constricted as a side effect of the medication, causing tears to accumulate excessively.
The persistent overflow of tears can disrupt daily life, as they fail to drain properly and instead spill over onto the face.
Continuous moisture can lead to irritation, infections, and may further impair vision through blurring and potential corneal damage.
Sanofi-Aventis, the producer of Taxotere, is accused of not adequately warning patients and healthcare professionals about the risk of severe eye injuries associated with its use.
Compensation in the Taxotere Lawsuit could vary widely, from $20,000 to several hundred thousand dollars per individual, influenced by specific circumstances and the overall progress of the litigation.
If you or someone you know has experienced eye injuries or vision loss following the use of Taxotere, you might qualify to participate in the Taxotere Eye Damage Lawsuits.
Additionally, you can utilize the chatbot on this page to instantly check if you are eligible for the Taxotere Vision Damage Lawsuit.
May 1, 2024
The Taxotere Eye Injury Lawsuit is currently active. According to the latest Judicial Panel on Multidistrict Litigation (JPML) filings, the number of pending Taxotere lawsuits remains at 268, with no change from the previous month.
If you or someone close to you has experienced eye injuries following the use of Taxotere, you may have grounds to file a lawsuit.
For a free, no-obligation consultation, please contact our law firm.
You can also use the chatbot on this page to determine if you qualify for the Taxotere Lawsuit.
The litigation surrounding Taxotere Eye Injury is still in progress.
Recent documents from the Judicial Panel on Multidistrict Litigation (JPML) reveal that the count of Taxotere Lawsuits grouped in the MDL stands steady at 268.
During March, there were no new cases of Taxotere Eye Injury added to the MDL. If Taxotere has negatively impacted you or someone you know, seeking legal advice may be a critical move.
For comprehensive details and to explore your legal options, we invite you to get in touch with our office for a no-charge consultation.
Additionally, you can utilize the chatbot on this website to immediately check your eligibility for a Taxotere Eye Injury Lawsuit.
The Taxotere Lawsuit is ongoing.
The Taxotere Eye Injury MDL is currently progressing, with a recent update indicating an increase in cases.
The Judicial Panel for Multidistrict Litigation (JPML) reported that as of February 1st, there were 258 consolidated lawsuits within the MDL, which grew to 268 by March 1st following the addition of ten new filings.
Multidistrict Litigations like this one are designed to efficiently process numerous lawsuits that share common issues, facts, or defendants, streamlining the legal proceedings for cases arising form similar circumstances.
In the context of the Taxotere Eye Injury Litigation, the lawsuits center around allegations against Sanofi-Aventis, the manufacturer of Taxotere.
Plaintiffs claim the company did not sufficiently inform patients and healthcare professionals about the potential risk of severe and permanent eye injuries, such as Canalicular Stenosis, associated with the chemotherapy drug.
These legal actions aim to address the grievances of individuals who believe they have suffered eye injuries due to Taxotere.
For those affected or believing to be impacted by Taxotere-related eye injuries, legal assistance is available.
Call now for a free consultation, or use the ChatBot on this page for immediate feedback.
January 15th, 2023:
There are now 258 pending cases in the Taxotere eye damage class action MDL. Only about 20 new cases have been added to this MDL since September.
December 1st, 2023:
No settlement payouts have been issued in the Taxotere lawsuits involving hair loss or vision loss litigations as of yet.
The hair loss cases remain consolidated under federal MDL 2740, and the eye injury cases under federal MDL 3023, both overseen by Judge Jane Triche Milazzo in Louisiana federal court.
November 17th, 2023:
The Taxotere litigation is ongoing, comprising 9,917 hair loss lawsuits and 249 lawsuits related to vision problems. These cases are currently consolidated into two separate MDLs in the federal court in Louisiana.
The pretrial negotiation phase is still in progress, and there are indications that a resolution for the Taxotere litigation may be possible by the end of the year.
As of now, there are 240 pending cases in the Taxotere Eye Injury Litigation, while the Taxotere Products Liability Litigation involves 10,209 cases.
Over the past month, the Eye Injury Litigation has seen an increase of 7 new cases, whereas the Product Liability Litigation has decreased by 201 cases.
October 2nd, 2023:
There are currently 240 pending cases in the Taxotere vision damage class action MDL, marking an increase of 17 cases from the previous month. This rise is in line with the typical monthly case intake observed in this MDL.
September 5th, 2023:
A study published in JAMA Ophthalmology supports claims by plaintiffs that Taxotere may cause optic neuropathy, CME, and epiphora, with the drug increasing watery eyes sevenfold. Sanofi argues that an eye injury warning was added to the label in 2002, but plaintiff attorneys contend that it inadequately addressed the risk of permanent tear duct injury linked to the drug.
August 1st, 2023
There have been no recent settlements in the class action lawsuit against Sanofi, the manufacturer of Taxotere.
Plaintiffs continue to step forward, claiming the cancer drug caused blurred vision, eye irritation, blurred vision, loss of vision, and other adverse health effects.
Recent dismissals in the New Jersey Taxotere MCL revealed that the bellwether plaintiffs’ cases were barred by the statute of limitations.
However, Sanofi, the creators of the chemotherapy drug, are still facing thousands of lawsuits in various jurisdictions.
Sanofi, the manufacturer of Taxotere, remains entangled in a significant number of lawsuits in the Federal Court of Louisiana, with over 10,600 cases relating to hair loss and 197 cases concerning eye damage attributed to the chemotherapy drug.
Thousands have lawsuits have been filed against the creators of Taxotere, Sanofi.
Cases are still pending.
Cases are still ongoing for the Taxotere lawsuit.
Sanofi did win their first bellwether case earlier this year in relation to chemotherapy hair loss.
However, there are still cases pending related to Sanofi’s failure to update the Taxotere warnings and label.
The judicial panel makes a separate panel that consolidates all watery cases into a specific MDL.
Sanofi wins its bellwether case related to chemotherapy hair loss litigation.
A judge allows a new trial for the class action lawsuit.
The plaintiff attorneys request the judicial panel to consolidate all watery eye cases into a separate MDL.
There are now a reported 170 plaintiffs that have filed for an eye injury lawsuit in the Taxotere MDL class action case.
Order filed in the U.S. District Court Eastern District of Louisiana.
According to the Order, the Court met recently with the parties’ liaison counsel to discuss several issues, including the litigation’s recent “Science Day.”
Science Days provide parties to large, complex litigations with the opportunity to inform the court regarding the medical and scientific issues that are central to their respective cases.
Science Day discussing the long-term side effects of Taxotere was held on May 3.
Presentations made during Science Days are typically off the record and non-adversarial in nature.
Other issues addressed in the April Taxotere lawsuit order included:
U.S. District Judge Kurt Engelhardt issued an order approving the 30-page fact sheet that plaintiffs will use going forward with their lawsuits against Sanofi, and appointed representatives of the plaintiffs and defendants to settlement committees, which will collaborate for potential resolution of the cases.
The next status conference for those committees is set for March 17, 2017.
Recent studies have uncovered a concerning link between the chemotherapy drug Taxotere (docetaxel) and certain side effects related to the eyes and tear ducts.
These findings highlight the importance of understanding the potential risks associated with this medication, particularly for patients undergoing treatment for various types of breast cancer and lung cancer.
Healthcare providers should be aware of these side effects and consider alternative treatment options or dosing schedules when appropriate.
Further research is needed to develop strategies to mitigate these side effects and improve patient outcomes while maintaining the effectiveness of cancer treatment with Taxotere.
Researchers at The University of Texas M.D. Anderson Cancer Center recognize canalicular stenosis may be the underlying mechanism for epiphora in patients receiving weekly doses.
Studies have found up to 50% of patients on this dosing schedule developing epiphora.
This is caused by the narrowing of the canaliculi, which are the small channels that drain tears from the eyes into the nose.
This side effect is more common with weekly administration compared to the standard every-3-weeks docetaxel regimen, with symptoms typically appearing 12-16 weeks after starting treatment.
Early diagnosis of canalicular stenosis allows for timely surgical intervention to insert silicone stents into the nasolacrimal ducts to prevent the canaliculi from closing permanently.
A study published in the Review of Ophthalmology found that weekly administration of Taxotere is far more likely to cause canalicular stenosis than administering it every three weeks.
Researchers looked at the evaluation and management of chemotherapy-induced epiphora, punctal and canalicular stenosis, and nasolacrimal duct obstruction. They selected abstracts based on relevant keywords and included appropriate articles for review.
The study demonstrated that 5-fluorouracil and docetaxel are the chemotherapeutic drugs best documented to cause epiphora, with the main mechanism being canalicular stenosis. Weekly administration of docetaxel was found to be more likely to cause this side effect compared to a three-week schedule.
Early recognition of punctal and canalicular stenosis or nasolacrimal duct blockages, along with early intervention using topical steroids and canalicular stenting in patients at risk for permanent scarring, is crucial to avoid more invasive procedures.
The researchers emphasize that early recognition and management of epiphora leads to better outcomes for patients undergoing chemotherapy with Taxotere.
Researchers from Kawasaki Medical School reported on a case series of three Japanese non-small cell lung cancer patients who developed epiphora after receiving docetaxel-based chemotherapy.
In one case, a patient with lacrimal puncta stenosis showed improvement with probing and irrigation. The other two patients had resolution of symptoms following cessation of docetaxel or administration of artificial tears.
The study highlighted that excessive tearing can interfere with daily life activities and negatively affect the quality of life of patients undergoing treatment with docetaxel.
Ophthalmological examination revealed that epiphora can occur with or without the presence of lacrimal duct obstruction. In cases without obstruction, the excessive tearing is considered a reactive response to ocular dryness.
The researchers suggest that the use of artificial tears may help wash out docetaxel from the ocular surface and prevent the development of lacrimal duct obstruction.
They emphasize the importance for thoracic oncologists to be aware of this adverse event and to conduct timely diagnosis and management to prevent severe lacrimal duct obstruction that may require complicated surgery.
The Taxotere label highlights several life-threatening side effects in the boxed warning, including toxic deaths, hepatotoxicity, neutropenia, hypersensitivity reactions, and fluid retention.
These severe adverse effects are of particular concern for patients and healthcare providers, as they can significantly impact the quality of life and overall survival of those undergoing cancer treatment with Taxotere.
A black box warning is the most serious type of warning issued by the FDA.
It is important for patients to be aware of these risks to monitoring and manage these potential side effects appropriately.
The risk of toxic death increases for patients with:
Hepatotoxicity is common in patients with:
Taxotere’s label warns that fluid retention may:
Patients with neutrophil counts under 1500 cells per 3 cubic millimeters of blood volume are:
Other potentially serious or fatal side effects of Taxotere include low blood cell counts and hypersensitivity reactions, while more common adverse effects include hair loss, cytopenia, numbness, shortness of breath, nausea, vomiting, and muscle pains.
Collecting evidence is a key step when pursuing a Taxotere vision damage lawsuit. Thorough documentation substantiating that you received Taxotere treatment and subsequently suffered vision impairment is essential for building a strong case.
Your Taxotere lawyers will provide guidance on what specific information to gather, but you can begin assembling relevant records and materials on your own to support your claim.
When gathering evidence for your Taxotere lawsuit, it is important to be thorough and comprehensive.
Your evidence should clearly demonstrate the link between your Taxotere treatment and the subsequent vision damage you experienced.
The following list outlines the key types of evidence that can support your case:
Beyond official medical documentation, keeping a journal of your experiences, challenges and medical appointments can also help paint a clearer picture of how Taxotere has affected your health and quality of life.
Contact TruLaw using the chat on this page to receive an instant case evaluation and determine you eligibility to join others in filing a Taxotere eye injury lawsuit today.
The more detailed evidence you can provide, the better we can advocate on your behalf.
In addition to the vision loss lawsuits, there is a separate multidistrict litigation (MDL) specifically addressing Taxotere hair loss lawsuits.
Plaintiffs in this hair loss MDL allege that the breast cancer chemotherapy drug Taxotere caused them to suffer permanent hair loss, a devastating side effect that can have a profound impact on a person’s quality of life and emotional well-being.
The Taxotere hair loss lawsuits are consolidated in MDL 2740, which is being heard in the US District Court for the Eastern District of Louisiana. This centralization allows for a more efficient handling of the numerous cases involving similar claims against the drug’s manufacturer.
Hair loss side effects associated with Taxotere for breast cancer treatment include:
These side effects can be emotionally traumatic for cancer survivors who have already endured the challenges of their diagnosis and treatment.
While TruLaw is actively pursuing Taxotere lawsuits related to vision loss and eye damage, we are not currently involved in the separate hair loss MDL 2740.
Their focus remains on representing plaintiffs who have suffered eye injuries after being treated with Taxotere, ensuring that these individuals receive the legal support and compensation they deserve.
You may be eligible to file a Taxotere lawsuits if you or a loved one has received Taxotere chemotherapy for breast cancer treatment or another type of cancer resulting in vision loss or other related eye problems such as severe pain in the eye area, sudden vision loss, swelling eyelids, soreness, or blurred vision.
Contact TruLaw using the chat on this page to receive an instant case evaluation and join other people filing Taxotere lawsuits today.
No, there is not a Taxotere class action lawsuit for eye injuries related to Taxotere use.
Instead, the Taxotere lawsuits have been consolidated into multidistrict litigation (MDL) in the US District Court for the Eastern District of Louisiana
In the case of a settlement in an MDL, compensation is distributed to plaintiffs according to the facts and damages of each individual case.
In contrast, class action lawsuit settlements divide compensation evenly among all plaintiffs, regardless of how they have been individually affected.
Taxotere Lawsuits for vision damage and eye injuries are consolidated into multidistrict litigation (MDL) in the US District Court for the Eastern District of Louisiana.
The Taxotere Eye Injury MDL (MDL 3023) alleges that Sanofi-Aventis did not adequately warn doctors or patients about the potential vision loss side effects of the drug.
Contact TruLaw using the chat on this page to receive an instant case evaluation and join others in filing a Taxotere lawsuit today.
Most Taxotere lawyers work on a contingency fee basis, which means you are not required to pay anything out-of-pocket for legal representation.
Under this arrangement, Taxotere lawyers do not charge for their services unless a settlement is won in your favor.
In other words, it’s a “no win, no fee” policy.
The label for Taxotere includes a black box warning, the most serious type of warning issued by the FDA, which highlights severe adverse effects such as toxic death, hepatotoxicity, fluid retention, and neutropenia.
These risks are of particular concern for patients and healthcare providers, as they can significantly impact the quality of life and overall survival of those undergoing cancer treatment with Taxotere.
When gathering evidence for your Taxotere lawsuit, it is important to collect medical records, treatment records, oncology records, proof of Taxotere use, photos and videos of injuries, and other supporting evidence.
The more detailed evidence you can provide, the better your Taxotere lawyers can advocate on your behalf.
Experienced Attorney & Legal SaaS CEO
With over 25 years of legal experience, Jessie is an Illinois lawyer, a CPA, and a mother of three. She spent the first decade of her career working as an international tax attorney at Deloitte.
In 2009, Jessie co-founded her own law firm with her husband – which has scaled to over 30 employees since its conception.
In 2016, Jessie founded TruLaw, which allows her to collaborate with attorneys and legal experts across the United States on a daily basis. This hypervaluable network of experts is what enables her to share reliable legal information with her readers!
You can learn more about the Taxotere Lawsuits by visiting any of our pages listed below:
Here, at TruLaw, we’re committed to helping victims get the justice they deserve.
Alongside our partner law firms, we have successfully collected over $3 Billion in verdicts and settlements on behalf of injured individuals.
Would you like our help?
At TruLaw, we fiercely combat corporations that endanger individuals’ well-being. If you’ve suffered injuries and believe these well-funded entities should be held accountable, we’re here for you.
With TruLaw, you gain access to successful and seasoned lawyers who maximize your chances of success. Our lawyers invest in you—they do not receive a dime until your lawsuit reaches a successful resolution!
Do you believe you’re entitled to compensation?
Use our Instant Case Evaluator to find out in as little as 60 seconds!
AFFF Lawsuit claims are being filed against manufacturers of aqueous film-forming foam (AFFF), commonly used in firefighting.
Claims allege that companies such as 3M, DuPont, and Tyco Fire Products failed to adequately warn users about the potential dangers of AFFF exposure — including increased risks of various cancers and diseases.
Suboxone Tooth Decay Lawsuit claims are being filed against Indivior, the manufacturer of Suboxone, a medication used to treat opioid addiction.
Claims allege that Indivior failed to adequately warn users about the potential dangers of severe tooth decay and dental injuries associated with Suboxone’s sublingual film version.
Social Media Harm Lawsuits are being filed against social media companies for allegedly causing mental health issues in children and teens.
Claims allege that companies like Meta, Google, ByteDance, and Snap designed addictive platforms that led to anxiety, depression, and other mental health issues without adequately warning users or parents.
Transvaginal Mesh Lawsuits are being filed against manufacturers of transvaginal mesh products used to treat pelvic organ prolapse (POP) and stress urinary incontinence (SUI).
Claims allege that companies like Ethicon, C.R. Bard, and Boston Scientific failed to adequately warn about potential dangers — including erosion, pain, and infection.
Bair Hugger Warming Blanket Lawsuits involve claims against 3M — alleging their surgical warming blankets caused severe infections and complications (particularly in hip and knee replacement surgeries).
Plaintiffs claim 3M failed to warn about potential risks — despite knowing about increased risk of deep joint infections since 2011.
Baby Formula NEC Lawsuit claims are being filed against manufacturers of cow’s milk-based baby formula products.
Claims allege that companies like Abbott Laboratories (Similac) and Mead Johnson & Company (Enfamil) failed to warn about the increased risk of necrotizing enterocolitis (NEC) in premature infants.
Here, at TruLaw, we’re committed to helping victims get the justice they deserve.
Alongside our partner law firms, we have successfully collected over $3 Billion in verdicts and settlements on behalf of injured individuals.
Would you like our help?
